Provided by Tiger Trade Technology Pte. Ltd.

VanEck Biotech ETF

239.49
+3.101.31%
Pre-market: 239.49-0.00180.00%04:56 EDT
Volume:28.69K
Turnover:6.84M
Market Cap:475.75M
PE:- -
High:239.49
Open:236.45
Low:236.45
Close:236.40
52wk High:244.35
52wk Low:160.91
Shares:1.99M
Float Shares:1.99M
Volume Ratio:3.93
T/O Rate:1.44%
Dividend:0.95
Dividend Rate:0.39%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

US FDA Approves Revolution Medicines' Pancreatic Cancer Drug

Reuters
·
Aug 26

FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer

THOMSON REUTERS
·
Aug 26

Revolution Medicines CEO Mark A. Goldsmith Reports Disposal of Common Shares Worth $16.87 Million

Reuters
·
Aug 26

Sino Biopharmaceutical Stock Climbs 2.1% in Hong Kong, Outperforms Competitors

Dow Jones
·
Aug 26

Gilead Sciences Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Aug 26

Moderna Inc. Stock Rallies 14.4%, Outperforms Peers

Dow Jones
·
Aug 26

Political and General News Events from August 25

Reuters
·
Aug 25

Sector Update: Healthcare Stocks Edge Higher Premarket Tuesday

MT Newswires Live
·
Aug 25

Stick with Value Stocks Until Everyone Starts Talking About Them - and as of Now They're Still Under the Radar, This Wall Street Firm Says

Dow Jones
·
Aug 25

Veeva Systems Secures Biogen, Regeneron Pharmaceuticals as New Vault CRM Clients

MT Newswires Live
·
Aug 25

Regeneron Selects Veeva Vault CRM for Global Rollout

Reuters
·
Aug 25

Viavi Solutions (VIAV) Could Be 40% Undervalued On Vertex 6.0 Launch

Simply Wall St.
·
Aug 25

Moderna Inc. Stock Slides 4.3%, Underperforms Peers

Dow Jones
·
Aug 25

Amgen Inc. Stock Underperforms Monday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Aug 25

Lakefront Biotherapeutics Wins FDA Orphan Drug Status for Gamgertamig in Pemphigus

Reuters
·
Aug 25

Amgen Extends MariTide Study In Obesity And Diabetes, Keeping Investor Focus On Long-Term Potential

TIPRANKS
·
Aug 25

Political and General News Events from August 24

Reuters
·
Aug 24

EU Commission Approves Gilead Trodelvy-Keytruda Combo for First-Line PD-L1+ Metastatic TNBC

Reuters
·
Aug 24

Gilead - EU Grants Marketing Authorization for Trodelvy with Keytruda in First-Line Pd-L1-Positive Metastatic Tnbc

THOMSON REUTERS
·
Aug 24

European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across Pd-L1 Status

THOMSON REUTERS
·
Aug 24